Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Details of Dr. Mendelsohn's presentation are as follows:
Date: Wednesday, September 10, 2025Time: 1:00 PM - 1:30 pm, Eastern TimeLocation: Lotte New York Palace Hotel, Holmes I - 4th Floor
Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance.
More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at https://hcwevents.com/annualconference/.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy.
Forward-Looking Statements
This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.
Company Contact:Donald DwyerChief Business Officerinfo@vivani.com(415) 506-8462
Investor Relations Contact:Jami TaylorInvestor Relations Advisorinvestors@vivani.com(415) 506-8462
Media Contact:Mark CorbaeICR HealthcareMark.Corbae@ICRHealthcare.com(203) 682-8288
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
a few seconds ago
- CNN
Timeline: The rise and fall of Target's fortunes
Target CEO Brian Cornell is stepping down after 11 years amid struggles at one of America's most prominent retail chains. Cornell helped engineer a turnaround at Target, but it's been a rocky few years for the retailer. Incoming Target CEO Michael Fiddelke, a veteran leader at the company, will have a tough task ahead as he faces tumbling sales, tariff pressure and a consumer slowdown. But Target has been in a deep slump for years, mostly due to its own strategic missteps. The company has quickly fallen behind rivals like Walmart, Amazon and Costco. Here's how Target reached new heights – and then fell – during Cornell's tenure.
Yahoo
28 minutes ago
- Yahoo
Fitzco Names Chris Wallrapp CEO
Executive joins the agency from Hill Holliday in Boston. ATLANTA, Aug. 20, 2025 /PRNewswire/ -- Fitzco, a BCG Worldwide agency, has named Chris Wallrapp as its new Chief Executive Officer, effective Sept. 8. Wallrapp joins from Hill Holliday Group in Boston where he has served as CEO since 2023 following more than a decade of leadership roles, including President and Chief Growth Officer. He will relocate to Atlanta to lead Fitzco's team into its next era of growth and creative success. BCG Worldwide CEO Tara DeVeaux, to whom Wallrapp will report, said what stood out about him was his stellar history of driving meaningful growth and the obvious enthusiasm he has for advertising. "It was clear from our first conversation that Chris loves this business. It's his superpower," DeVeaux said. "There was an extensive search to find the right fit for Fitzco and this ball of energy from Texas stood out. His track record of building meaningful relationships with new and existing clients made it clear he would be a transformational leader as Fitzco enters this next chapter of explosive growth." Over the course of his career, Wallrapp has worked in strategic growth roles at agencies including Modernista, Fallon, Carmichael Lynch, Y&R, and GSD&M. He has been recognized on AdAge's 40 Under 40 (2014) and Campaign US's 40 Over 40 lists (2021). "This is a dream opportunity to lead an agency with Fitzco's talent, creativity, and ambition," Wallrapp said. "The culture here is electric, and with Tara's vision and BCG Worldwide in our corner, we have the kind of advantage that sets us apart in an industry changing faster than ever. It's that combination of people and purpose that makes this moment so exciting for me." During his 14 years at Hill Holliday, Wallrapp led the agency to more than 120 new business wins, including Cadillac, Bank of America, Major League Baseball, Optum Health, and Kay Jewelers. Wallrapp takes the helm at a transformational moment. Founded in 1983 by Dave Fitzgerald, Fitzco was sold to IPG in 1998. In 2020, Fitzgerald came out of retirement to reacquire the agency and serve as CEO, later handing the reins to longtime staffer Evan Levy in 2023. When Burrell Communications Group formed BCG Worldwide and acquired Fitzco in April 2025, Levy retired, and Fitzgerald returned as interim CEO during the search for a permanent leader. The agency was named a Small Agency of the Year by AdAge in 2022. BCG Worldwide was founded by Channing Johnson's View Park Capital and FVLCRUM Partners, d.b.a. FVLCRUM Funds Capital Group, a private equity firm that intentionally invests in lower-middle market companies to generate sustainable opportunity. ABOUT FITZCOFounded in 1983 in Atlanta, Georgia, Fitzco is owned by BCG Worldwide and specializes in marketing and brand strategy, media planning and buying, data and analytics, content ideation, production, and design. Fitzco's ethos is to Make It Matter by delivering both conventional and unconventional business solutions for its clients, which include Madison Reed, Slim Fast Southern Company, Waymo, and Welch's. For more information, visit ABOUT BURRELL COMMUNICATIONS GROUPBurrell Communications Group was founded in 1971 by renowned ad man Tom Burrell, who led the company for 33 years. Today, Burrell Communications Group is the largest U.S. Black-owned agency specializing in understanding and speaking to today's market, one that is more diverse and more multicultural than ever before in our country's history. The agency boasts a roster of premiere, blue-chip clients that lead in their respective categories, including Toyota, Comcast, Deloitte, Coca-Cola, Microsoft, Exact Sciences and the American Red Cross. For more information, visit View original content to download multimedia: SOURCE Fitzco
Yahoo
28 minutes ago
- Yahoo
Viking's Premium Valuation Backed By Strong Growth, Analyst Notes
Viking Holdings Ltd (NYSE:VIK) shares slipped on Wednesday despite the cruise operator posting a strong second-quarter revenue jump and upbeat analyst commentary. The company reported an 18.5% year-over-year sales increase to $1.88 billion and reaffirmed its ability to sustain mid-single-digit pricing strength across its segments. While Bank of America Securities reiterated a Buy rating with a $70 target, citing Viking's premium positioning and superior returns, investors appeared cautious as shares traded nearly 2% lower in midday noted that Viking's premium positioning should help sustain pricing power, leading to only slight adjustments in 2025-2027 revenue and earnings forecasts. Pricing trends were mixed. River segment pricing improved by 200bps to +6%, likely supported by its dominant market share and mix benefits, while Ocean segment pricing slipped to +4% from +5%, which Didora suggested may reflect rising competition from other cruise operators. Concerns raised last quarter about 2026 pricing stability eased, as Viking maintained its +4% outlook while reinforcing expected mid-single-digit gains. Didora added that Viking is positioned to expand 2025 EBITDA by over 25%, with 2026-2027 estimates growing in the mid-teens, well above the high-single to low-double-digit growth expected for other cruise lines. He also pointed out that Viking's return on invested capital and EBITDA per APCD are nearly twice the industry average. 'We believe VIK's growth and financial metrics justify a premium valuation to peers,' Didora noted. Price Action: VIK shares are trading lower by 1.92% to $58.09 at last check Wednesday. Read Next:Photo by dreakrawi via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Viking's Premium Valuation Backed By Strong Growth, Analyst Notes originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
